Last reviewed · How we verify
Nebulized Salbutamol
Salbutamol is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing relaxation and bronchodilation.
Salbutamol is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing relaxation and bronchodilation. Used for Acute bronchospasm and asthma exacerbation, Chronic obstructive pulmonary disease (COPD) with airway obstruction, Reversible airway obstruction in reactive airway disease.
At a glance
| Generic name | Nebulized Salbutamol |
|---|---|
| Sponsor | Hospital General Naval de Alta Especialidad - Escuela Medico Naval |
| Drug class | Beta-2 adrenergic agonist (short-acting) |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Salbutamol activates beta-2 adrenergic receptors on bronchial smooth muscle cells, triggering a cascade that increases intracellular cAMP and leads to smooth muscle relaxation. This results in rapid airway dilation and improved airflow. When nebulized, the drug is delivered directly to the lungs as an aerosol, providing quick onset of action for acute bronchospasm relief.
Approved indications
- Acute bronchospasm and reversible airway obstruction in asthma
- Chronic obstructive pulmonary disease (COPD) exacerbations
- Acute dyspnea relief in obstructive airway disease
Common side effects
- Tremor
- Tachycardia
- Headache
- Nervousness or anxiety
- Palpitations
- Muscle cramps
Key clinical trials
- Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis (PHASE1, PHASE2)
- The Effect of NAC on Lung Function and CT Mucus Score (PHASE4)
- Randomized Controlled Trial Comparing Standard Versus Positive Pressure Nebulization in Infants With Bronchiolitis to Reduce Hospital Admissions (NA)
- Evaluation of the Effectiveness of the Nebulization Bronchodilators Under High Nasal Flow Humidified (NA)
- the Inhaled β2-adrenergic Receptor Agonist for Transient Tachypnoea of the Newborn (the REFSAL Trial) (PHASE3)
- BiPAP in Pediatric Moderate to Severe Asthma Randomized Control Trial (NA)
- Nebulized Ketamine Plus Standard Care vs. Standard Care Alone in Moderate to Severe Asthma Exacerbations (PHASE2)
- The Effect of Nebulized Epinephrine in Asthma Exacerbation in Pediatric Age Group With the Standard Treatment Compared to Standard Treatment Using Improvement PRAM Score as a Primary Outcome (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: